COVID-19 and anti-SARS-CoV-2 vaccination in patients with inborn errors of immunity in Granma

Authors

Keywords:

errores innatos de la inmunidad, enfermedades de inmunodeficiencia primaria, COVID-19, vacuna SARS-CoV-2

Abstract

Introduction: Patients with inborn errors of immunity constitute a particularly vulnerable group to SARS-CoV-2 infection, hence its adequate immunization holds paramount importance.

Objective: To describe anti-SARS-CoV-2 vaccination and clinical features of COVID-19 in patients with inborn errors of immunity in Granma province.

Methods: A descriptive, retrospective observational investigation was conducted, in a universe of 41 patients with inborn errors of immunity, treated at the Immunology practice of Granma province from April 2020 to June 2022. Data were collected through questioning of parents and patients and the study of secondary sources; the information was processed using the statistical package IBM SPSS Statistics v. 25.0.

Results: Anti-SARS-CoV-2 vaccine coverage in patients with inborn errors of immunity was 97.6%; all patients received Cuban vaccines. Adverse events were reported in 17.5% of immunized patients, of mild intensity in all cases, 52.1% were local. 19.5% patients were positive for SARS-CoV-2, 62.5% were asymptomatic; there was a severe case. The most frequent clinical manifestation was rhinitis; diarrhea, cough, fever, dyspnea and headache were also reported. All patients recovered favorably from COVID-19.

Conclusions: Anti-SARS-CoV-2 immunization with Cuban vaccines in patients with inborn errors of immunity was safe and achieved high coverage. The clinical evolution of the majority of patients who suffered from COVID-19 was favorable.

Downloads

Download data is not yet available.

Published

2025-12-30

How to Cite

1.
Pérez Acevedo LC, Addine Ramirez B de la C, González Costa M, Marrón Gonzalez R. COVID-19 and anti-SARS-CoV-2 vaccination in patients with inborn errors of immunity in Granma. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2025 Dec. 30 [cited 2025 Dec. 31];41:e1988. Available from: https://revhematologia.sld.cu/index.php/hih/article/view/1988

Issue

Section

INMUNOLOGÍA